Financial Snapshot
What do Pfizer Inc.’s latest financial health metrics show?
Pfizer Inc.’s financial health looks Mixed. The strongest factor is liquidity, supported by $1308B in cash and short-term investments, while the main concern is the heavy debt load and patent-cliff revenue risk.
For the 2026-03-29 period, the verdict blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. First-quarter 2026 revenue was $145B, up 5% year over year, and the broader picture also reflects the company’s cost-savings plan and dividend support. For mission and values context, see Mission Statement, Vision, & Core Values (2026) of Pfizer Inc. (PFE).
Start with free cash flow, because it best shows whether Pfizer Inc. can fund dividends, debt service, and growth without strain; Total Dividends Paid in 2025 was $98B, and the Q2 2026 cash dividend is $043 per share payable June 12, 2026.
Revenue and Earnings Quality
Are Pfizer Inc. revenue and earnings quality improving?
Mixed. Pfizer Inc. is showing better underlying non-COVID growth, but COVID normalization and loss-of-exclusivity pressure still weaken the overall earnings picture. The clearest confirmation is 6% operational growth in the non-COVID portfolio, while full-year 2026 guidance still signals transition pressure.
Revenue quality is improving in the parts of the business tied to oncology, immunology, and metabolic diseases, but the company is still working through a weaker COVID contribution and patent-driven pressure. Investors compare revenue durability with operating income, net income, and EPS across the same periods because growth only matters if it turns into lasting profit and per-share cash generation.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $1445B at 2026-03-29 | $1756B at 2025-12-31 | Unclear on a like-for-like sequential basis; full-year 2025 revenue was $626B with a 2% operational decline, while non-COVID portfolio revenue grew 6% operationally. | Non-COVID growth looks more repeatable, but COVID normalization still limits top-line durability. |
| Operating Income | $403B | $369B | Grew faster than revenue on the supplied sequential comparison. | That suggests better operating leverage in the latest quarter. |
| Net Income | $269B | -$165B | Improved sharply, with the move from a loss to profit indicating better bottom-line conversion. | Final earnings confirm that recent operating performance was stronger. |
| Diluted EPS | $047 at 2026-03-29 | -$029 | Share-count effects did not prevent per-share improvement. | Shareholders saw better per-share results in the latest quarter. |
How durable is Pfizer Inc. revenue?
The strongest durability signal is the 6% operational growth in the non-COVID portfolio. The biggest limitation is concentration risk from COVID normalization and loss-of-exclusivity pressure, even with 108 pipeline programs.
- Demand Quality: Recurrence is strongest in oncology, immunology, and metabolic diseases, but COVID-related demand is less reliable.
- Pricing and Volume: The split is not fully available here; verified growth is described as operational in the non-COVID portfolio.
- Diversification: Revenue is supported by multiple therapeutic areas and 108 pipeline programs, including 30 in Phase 3 and 3 pending regulatory approval.
That mix matters because profitability and cash conversion depend on whether non-COVID revenue can keep rising faster than legacy pressure falls. If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help organize the evidence.
Cash Conversion
Can Pfizer's profitability still convert into usable cash?
Not cleanly right now: profitability is being managed through cost realignment, but the supplied 2026-03-29 cash-flow growth lines are negative, so reported earnings are not clearly translating into usable cash on the data given.
Profitability and cash flow are not the same thing. Pfizer Inc. (PFE) can still report strong gross profit and operating income while net income is shaped by taxes and other items, but operating cash flow and free cash flow show whether earnings turn into cash after working capital and capital spending. For background, see Pfizer Inc. (PFE): History, Ownership, Mission, How It Works & Makes Money.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable from supplied data for 2026-03-29. | Unavailable from supplied data. | Cost of revenue was $473B against Revenue: $1445B, but no source-supplied gross-margin percentage was provided. | Product economics look pressured by manufacturing and input costs, but the exact margin trend cannot be verified here. |
| Operating Margin | Unavailable from supplied data for 2026-03-29. | Unavailable from supplied data. | R&D prioritization, SG&A reductions, and manufacturing savings are the stated relief levers, including a $77B cost-savings target through 2027. | Scale and cost discipline should improve efficiency if savings hold, but the margin percentage is not supplied. |
| Net Margin | Unavailable from supplied data for 2026-03-29. | Unavailable from supplied data. | Income Before Tax: $317B, Income Tax Expense: $46100M, and Net Income: $269B show final profit after tax, but no net-margin percentage was supplied. | Final profitability exists, but the exact conversion from sales to bottom-line earnings cannot be checked from the provided data. |
| Operating Cash Flow | Operating Cash Flow Growth: -5111% for 2026-03-29. | Previous comparable value not supplied. | No dollar operating cash flow figure was supplied, so the negative growth line is the only verified cash signal. | Accounting earnings are not clearly converting into operating cash on the supplied data. |
| Free Cash Flow | Free Cash Flow Growth: -5162% for 2026-03-29. | Previous comparable value not supplied. | No cash-flow amount or capex amount was supplied; manufacturing optimization is expected to deliver $600M in net cost savings by year-end 2025. | Less free cash means less room for dividends, debt reduction, and reinvestment if the weakness persists. |
What most affects Pfizer's cash conversion?
Working-capital pressure and heavy cost structure are the biggest verified issues, while manufacturing savings and SG&A cuts are the main offsets. The negative 2026-03-29 cash-flow growth lines suggest the turnaround is still incomplete.
- Main Driver: Cost realignment, especially $12B in SI&A reduction, $500M in R&D cost cuts, and $600M in manufacturing savings; this looks structural if sustained.
- Evidence Gap: No dollar operating cash flow, free cash flow, capex, or working-capital figure was supplied.
- Metric to Monitor: Operating cash flow, free cash flow, and working-capital movement.
Balance Sheet Health
Does Pfizer have enough liquidity to manage debt and dividends?
Mixed. Pfizer has enough liquidity to cover near-term needs, but debt remains material and keeps deleveraging central. The main protection is $1308B in cash and short-term investments; the main concern is $6446B of total debt after the Seagen acquisition, plus ongoing interest expense pressure.
Cash alone is not enough here. Pfizer needs a full read on working capital, asset quality, debt service, solvency, liquidity, and refinancing capacity together. That is especially important when dividends compete with debt reduction and when acquired assets must keep performing. For mission context, see Mission Statement, Vision, & Core Values (2026) of Pfizer Inc. (PFE).
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash and Short Term Investments: $1308B; Total Current Assets: $4282B; Total Current Liabilities: $3435B; Net Receivables: $1259B; Inventory: $1067B. | Mixed | Near-term obligations look manageable without forcing an immediate cut to investment. |
| Total and Net Debt | Short Term Debt: $389B; Long Term Debt: $6057B; Total Debt: $6446B; Cash and Cash Equivalents: $170B. | Mixed | Leverage is still high, so flexibility is limited even with strong liquidity. |
| Debt Service and Refinancing | Interest Expense: $66800M; Net Interest Income: -$55400M; Debt Growth: -439% at 2026-03-29, after 924% at 2025-12-31. | Mixed | Debt service looks manageable, but interest pressure makes refinancing and deleveraging important. |
| Asset Quality | Goodwill: $7141B; Intangible Assets: $5256B; Goodwill And Intangible Assets: $12397B. | Mixed | Asset quality depends heavily on pipeline execution and acquired-product performance. |
| Liabilities and Equity | Total current liabilities are $3435B, and the balance sheet carries large acquired-asset balances alongside debt tied to the Seagen acquisition. | Mixed | The capital base can absorb pressure, but it is not a low-risk balance sheet. |
Which balance-sheet risk matters most for Pfizer?
Debt load is the main risk. Liquidity is adequate, but the combination of $6446B total debt and $66800M interest expense keeps deleveraging ahead of dividend growth in importance.
- Current Exposure: Cash and Short Term Investments: $1308B against Total Current Liabilities: $3435B.
- Protection: Strong near-term liquidity, led by $4282B in total current assets.
- Warning Signal: Watch total debt and interest expense if cash flow weakens.
Capital Efficiency
Are Pfizer's returns strong enough to fund reinvestment?
Capital efficiency looks Mixed. Source-supplied ROIC, ROE, and ROA values are not provided, so they cannot be calculated here. Internal cash generation appears likely to cover much of reinvestment, but growth spending and deal activity could still require careful capital discipline.
Return measures have to be read alongside leverage, asset intensity, capital expenditure, working capital, and any outside funding need. For Pfizer, the question is not only whether earnings are improving, but also whether cash flow, balance sheet flexibility, and cost savings can support the oncology pivot without adding unnecessary debt or dilution.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable; no source-supplied ROIC value is provided. | Operating margins and capital efficiency cannot be tested directly without a verified ROIC figure. | Investors should treat invested-capital efficiency as unproven until a reported ROIC is available. |
| ROE and ROA | Unavailable; no source-supplied ROE or ROA values are provided. Net Income: $269B at 2026-03-29; Total Assets: $20762B; Book Valueper Share Growth: 403%; Asset Growth: -026%; Debt Growth: -439%. | ROE can be inflated by leverage, while ROA depends on how much profit Pfizer squeezes from its asset base. | Shareholder return quality and asset efficiency look hard to judge from the supplied data alone. |
| Maintenance and Growth Investment | Research And Development Expenses: $263B; Growth Capital Expenditure: 4840%; planned approximately 20 key pivotal study starts for 2026 after 11 starts in 2025; oncology pivot includes Seagen antibody-drug conjugate platform and obesity candidate PF-3944. | R&D and capex point to heavy reinvestment, but the maintenance-versus-growth split is not fully disclosed. | Pfizer appears to be funding a sizable pipeline push, especially in oncology, through ongoing internal investment. |
| Internal Funding Capacity | Funding sources are internal cash generation, cost savings, liquidity, and debt reduction; no planned repurchases. Share Repurchase Authorization Remaining: $33B with no share repurchases completed in 2025 or planned for 2026. | Investment looks mostly internally funded, with acquisition capacity as a backup rather than a first resort. | Capital flexibility appears decent, but buybacks are paused and outside funding would weaken shareholder returns. |
Are Pfizer's returns on capital sustainable?
The strongest durability source is internal cash generation tied to the oncology pipeline and cost savings. Returns weaken if acquisition spending, a larger debt load, or weak clinical execution forces more external funding or lowers earnings quality.
- Operating Source: Oncology mix, Seagen ADC assets, and PF-3944 can support margins if pivotal studies convert into sales.
- Funding Requirement: The biggest verified capital need is R&D and growth spending tied to approximately 20 key pivotal study starts in 2026.
- Durability Test: Returns would weaken if cash flow fails to cover reinvestment, or if leverage rises while ROA stays pressured by a large asset base.
Patent and cash strain
How resilient is Pfizer, and which warning signs matter most?
Mixed. Pfizer’s main buffer is its pipeline and cost-savings plan, but the most important verified warning sign is $17B–$20B in annual revenue at risk from loss of exclusivity during 2026–2030, including Prevnar 13 and Xeljanz.
Pfizer can still fund operations and investment, but resilience weakens if non-COVID product growth does not replace patent losses fast enough. The company’s profile matters for readers studying defensiveness, and the investor angle is covered in Exploring Pfizer Inc. (PFE) Investor Profile: Who's Buying and Why?.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Loss of exclusivity can cut operating leverage, lower earnings, reduce cash flow, and weaken debt capacity if replacement sales lag. | Oncology expansion, Seagen ADC integration, Vyndamax settlement extending effective US exclusivity to June 01, 2031, and broad pipeline breadth. | Weak non-COVID revenue growth or poor product-level replacement revenue. |
| Working-Capital or Investment Pressure | Weak cash conversion can absorb cash needed for R&D, manufacturing, and launches, especially if working capital stays heavy. | $77B cost-savings target through 2027 and manufacturing optimization support internal funding capacity. | Operating cash flow after working-capital changes trending lower. |
| Interest or Refinancing Pressure | Higher debt and interest expense can squeeze free cash flow and reduce financing flexibility if rates or maturities worsen. | Debt growth of -439% and no planned 2026 buybacks help preserve balance-sheet flexibility. | Total debt rising or interest expense staying elevated. |
What financial warning signs should investors monitor at Pfizer?
The top signals are patent-loss replacement revenue, then operating cash flow after working-capital changes, then debt and interest expense. The first two show confirmed deterioration if growth stays weak; the third is a future risk if financing pressure rises.
Patent cliff replacement gap
Pfizer faces $17B–$20B in annual revenue at risk from 2026–2030, with Prevnar 13 and Xeljanz adding pressure. Oncology, Seagen, and Vyndamax help, but investors should watch non-COVID revenue growth.
Cash conversion weakness
Operating Cash Flow Growth: -5111% and Free Cash Flow Growth: -5162% point to sharp cash strain. The $77B savings plan helps, but the next metric is operating cash flow after working-capital changes.
Debt and interest burden
Total Debt: $6446B, Long Term Debt: $6057B, Interest Expense: $66800M, and Net Interest Income: -$55400M show a heavy financing load. Monitor total debt trend and interest expense for refinancing pressure.
Mixed Health
What does Pfizer's financial health mean for investors?
Pfizer gets a Mixed rating. The strongest factor is liquidity and cost realignment, while the weakest is patent-cliff replacement risk. The most important condition is whether cash conversion can stay strong enough to fund the dividend, debt service, and pipeline investment.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | Non-COVID portfolio revenue grew 6% in full-year 2025, and first-quarter 2026 revenue was $145B, but guidance of $595B-$625B still trails 2025 levels. |
| Profitability and Cash | Mixed | Operating income of $403B and net income of $269B improved, but operating cash flow growth of -5111% and free cash flow growth of -5162% show weak conversion. |
| Balance Sheet and Liquidity | Mixed | Cash and short term investments of $1308B provide flexibility, but total debt of $6446B and interest expense of $66800M keep leverage and servicing costs material. |
| Capital Efficiency | Mixed | No ROIC, ROE, or ROA data is supplied, so returns are harder to judge; execution depends on Seagen integration, R&D priorities, and cost savings. |
| Financial Resilience | Mixed | Buffers exist, but $17B-$20B in annual revenue at risk from LOE is large, so replacement products and cash conversion matter most. |
- What Supports the Thesis: Liquidity, cost realignment, and dividend funding capacity give Pfizer room to manage near-term pressure.
- What Challenges the Thesis: Cash conversion is weak, and patent-cliff replacement risk remains the main uncertainty.
- What to Monitor: Non-COVID Portfolio Revenue Growth, Free Cash Flow Growth, Total Debt.
For forecasts and scenarios, the key question is whether Pfizer can convert revenue recovery into steadier cash flow and lower dependence on debt-funded support, which will shape any valuation model.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How much cash remains after Pfizer's capex?
The supplied data gives Free Cash Flow Growth: -5162% for 2026-03-29, not a free cash flow dollar amount Treat post-capex cash generation as pressured, then verify the full cash flow statement before estimating dividend capacity, debt repayment, or acquisition flexibility
Is Pfizer's dividend covered by cash generation?
Dividend support is still plausible, but the evidence is mixed Pfizer paid Total Dividends Paid in 2025: $98B and declared $043 per share for Q2 2026, while Free Cash Flow Growth: -5162% shows weaker latest-period cash conversion
Can Pfizer fund pipeline growth while deleveraging?
Pfizer has liquidity support from Cash And Short Term Investments: $1308B and showed Debt Growth: -439% at 2026-03-29 Funding remains execution-dependent because the company also plans approximately 20 key pivotal study starts for 2026 and carries Total Debt: $6446B
Which expiries pressure Pfizer's financial health?
The largest issue is the 2026–2030 patent cliff, with estimated $17B–$20B in annual revenue at risk Specific pressures include Prevnar 13 and Xeljanz, while Vyndamax litigation settlement extends effective US exclusivity to June 01, 2031
Do Pfizer's returns depend on leverage?
No ROIC, ROE, or ROA values are supplied, so returns should not be calculated here The balance sheet shows Total Debt: $6446B, meaning future return quality depends on earnings growth, cost savings, acquired asset productivity, and lower funding pressure